Additional Measles Vaccine at 4 Months of Age

Conditions

Measles Infection

Keywords

Mortality, Morbidity, Hospitalisations/consultations, Growth, Measles infection

Brief summary

Overall objective: To conduct a randomised controlled trial (RCT) to examine whether an early two-dose measles vaccination (MV) strategy at 4 and 9 months will reduce child mortality compared with the WHO strategy of one dose of MV at 9 months. Specific hypotheses Hypothesis I) Two doses of MV at 4 and 9 months compared with the standard dose of MV at 9 months will reduce mortality by 30% between 4 months and 5 years of age1. As in a previous trial it is expected that the beneficial effect is strongest for girls. Hypothesis II) Children receiving MV at 4 months in the presence of maternal measles antibodies (MatAb) will have 35% lower mortality between 4 months and 5 years of age than children receiving MV at 4 months with no detectable MatAb. Implications: These hypotheses are based on a previous RCT showing strong beneficial effects of providing an early measles vaccine, in particular among children with MatAb.

Nielsen S, Fisker AB, da Silva I, Byberg S, Biering-Sørensen S, Balé C, Barbosa A, Bjerregaard-Andersen M, Hansen NS, Do VA, Bæk O, Rasmussen SM, Damkjær L, Hvidt S, Baltzersen O, Rodrigues A, Martins C, Jensen KJ, Whittle HC, Smits G, van der Klis F, Aaby P, Benn CS.

2022-05-2718 citations

10.1016/j.eclinm.2022.101467

Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau

Nadja Skadkær Hansen, Stine Byberg, Lars Hervig Jacobsen, Morten Bjerregaard-Andersen, Aksel Karl Georg Jensen et al. (10 authors)

PLoS ONE2017-05-1719 citations

10.1371/journal.pone.0177547

The effect of early measles vaccination on thymic size. A randomized study from Guinea-Bissau.

Christensen LD, Eriksen HB, Biering-Sørensen S, Balé C, Do VA, Andersen A, Martins CL, Sodemann M, Aaby P, Benn CS.

2014-02-091 citations

10.1016/j.vaccine.2014.01.034

Interventions

BIOLOGICALMeasles vaccine

Edmonston-Zagreb measles vaccine

Study design

Allocation

RANDOMIZED

Primary purpose

PREVENTION

Eligibility

Sex/Gender

ALL

Age

4 Months to 7 Months

Inclusion criteria

* Children aged 4 to 7 months who received the third dose of pentavalent vaccine at least 4 weeks earlier

Exclusion criteria

* Malformations * Severely ill * Severely malnourished

Design outcomes

Primary

Measure	Time frame	Description
Mortality	—	Differences in mortality rates between the intervention and control groups

Secondary

Measure	Time frame	Description
Morbidity	—	Symptoms of infection
Hospitalisations/consultations	—	Visits to health center for consultation due to illness, hospitalisation
Growth	—	Weight, length, arm circumference
Measles infection	—	Measles infection assessed by medical doctor and/or verified by blood samples

Countries

Guinea-Bissau

Contacts

Primary ContactPeter Aaby, DMSc

p.aaby@bandim.org+45 3268 3950

Backup ContactChristine S Benn, MD, PhD

cb@ssi.dk+45 3268 8354

Outcome results

None listed